* clinically diagnosed olfactory dysfunction secondary to genetic abnormalities or congenital dysfunction, trauma, non-covid-19 viral infection, nasal polyps, neurodegenerative disorders * current use of: azelastine, bromperidol, orophenadrine, oxomemazine, kratom, paraldehyde, or thalidomide * history of addiction to alcohol, cocaine, or opioids * impaired renal function, myasthenia gravis, or myoclonus * severe allergy to peanuts * pregnancy or attempting pregnancy during study participation * inability to participate in virtual trial due to lack of access to the internet or unlimited text messaging; inability to comprehend or use english language * availability less than 6 months from time of enrollment * residency in states other than missouri or illinois.

* clinically diagnosed olfactory dysfunction secondary to genetic abnormalities or congenital dysfunction, trauma, non-covid-19 viral infection, nasal polyps, neurodegenerative disorders * current use of: azelastine, bromperidol, orophenadrine, oxomemazine, kratom, paraldehyde, or thalidomide * history of addiction to alcohol, cocaine, or opioids * impaired renal function, myasthenia gravis, or myoclonus * severe allergy to peanuts * pregnancy or attempting pregnancy during study participation * inability to participate in virtual trial due to lack of access to the internet or unlimited text messaging; inability to comprehend or use english language * availability less than 6 months from time of enrollment * residency in states other than missouri or illinois.

clinically diagnosed olfactory dysfunction secondary to genetic abnormalities or congenital dysfunction, trauma, non-covid-19 viral infection, nasal polyps, neurodegenerative disorders current use of: azelastine, bromperidol, orophenadrine, oxomemazine, kratom, paraldehyde, or thalidomide history of addiction to alcohol, cocaine, or opioids impaired renal function, myasthenia gravis, or myoclonus severe allergy to peanuts pregnancy or attempting pregnancy during study participation inability to participate in virtual trial due to lack of access to the internet or unlimited text messaging; inability to comprehend or use english language availability less than 6 months from time of enrollment residency in states other than missouri or illinois.

clinically diagnosed olfactory dysfunction secondary to genetic abnormalities or congenital dysfunction, trauma, non-covid-19 viral infection, nasal polyps, neurodegenerative disorders current use of: azelastine, bromperidol, orophenadrine, oxomemazine, kratom, paraldehyde, or thalidomide history of addiction to alcohol, cocaine, or opioids impaired renal function, myasthenia gravis, or myoclonus severe allergy to peanuts pregnancy or attempting pregnancy during study participation inability to participate in virtual trial due to lack of access to the internet or unlimited text messaging; inability to comprehend or use english language availability less than 6 months from time of enrollment residency in states other than missouri or illinois.